What are various Exocrine Pancreatic Insufficiency (EPI) Therapeutics available in market today?
Exocrine
pancreatic insufficiency is a medical condition where a person has a functional
insufficiency for some reason such as having too little insulin in his body,
then the pancreas will be unable to secrete sufficient amounts of insulin. This
means that there is not enough glucose in the blood to provide the body with
energy. When the body cannot absorb glucose, cells will starve to death. This
causes damage to the pancreas, liver, and other organs of the body until a
dysfunctional condition develops into Pancreatitis, which is an inflammation of
the abdominal wall, pancreas, liver, or other organs.
There
are many Exocrine
Pancreatic Insufficiency (EPI) Therapeutics available in the market. One
such drug, methotrexate, is often used in conjunction with insulin therapy. The
goal of treatment with drugs is to reduce blood sugar levels and increase
insulin so that cells can properly absorb glucose, making the body function
normally again. Such treatments may be useful in relieving symptoms of Exocrine
Pancreatic Insufficiency when they are administered after surgery.
However,
some drugs can raise the risk of Exocrine Pancreatic Insufficiency. One drug,
varenicline, is given to reduce nausea in people with diabetes. When taken by
diabetics, it can increase the risk of heart attacks, strokes, excessive weight
gain, kidney failure, and even liver disease. Other drugs such as prednisone
and other immune suppressants can also make Exocrine Pancreatic Insufficiency
worse.
In
addition to using pancreatic enzyme injections, other Exocrine Pancreatic
Insufficiency (EPI) Therapeutics may be available in the future for treating
Exocrine Pancreatic Insufficiency. For instance, immunosuppressant drugs have
been shown to slow down the progression of diabetes, and doctors often use
these drugs to treat patients with autoimmune disorders such as multiple
sclerosis, Lupus, and rheumatoid arthritis.
Comments
Post a Comment